LifeSci Capital analyst Sam Slutsky has maintained their bullish stance on VTYX stock, giving a Buy rating today.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Sam Slutsky’s rating is based on several promising developments at Ventyx Biosciences. The company has shown encouraging progress with its CNS-penetrant NLRP3 inhibitor, VTX3232, which demonstrated target engagement and safety in a Phase 2a study for early Parkinson’s disease. This success is further supported by plans to present these findings at significant medical conferences and the initiation of a placebo-controlled Phase 2 study in Parkinson’s disease, as well as evaluations in other neurodegenerative disorders like Alzheimer’s disease.
Additionally, Ventyx is advancing its peripherally restricted NLRP3 inhibitor, VTX2735, in a Phase 2 study for recurrent pericarditis, with results expected in Q4 2025. The company’s strategic focus on addressing inflammation and cardiometabolic biomarkers through innovative trials, combined with a solid financial position, underscores the potential for significant growth and development, justifying the Buy rating.
In another report released today, Oppenheimer also reiterated a Buy rating on the stock with a $9.00 price target.